What is the appropriate antiviral treatment regimen and duration for eczema herpeticum?

Treatment and Duration of Eczema Herpeticum

Eczema herpeticum requires immediate systemic acyclovir therapy based on clinical suspicion alone, without waiting for laboratory confirmation, to prevent potentially life-threatening complications including dissemination, ocular involvement, and death.

Clinical Recognition

Eczema herpeticum presents as painful, monomorphic vesiculopustules that rapidly spread across eczematous and previously unaffected skin, typically accompanied by fever and malaise 1, 2. The condition carries a mortality rate exceeding 50% if left untreated 2. Do not delay treatment for laboratory confirmation—clinical diagnosis is sufficient to initiate therapy.

Treatment Regimens

Mild to Moderate Disease (Outpatient)

Oral acyclovir 200 mg five times daily for 5-10 days 3, 4

• This regimen demonstrated 81.3% efficacy versus 42.9% for placebo in controlled trials 4
• Continue until complete lesion healing is achieved 3
• In children <45 kg: acyclovir 20 mg/kg (max 400 mg/dose) orally three times daily for 5-10 days 3

Moderate to Severe Disease (Inpatient)

Acyclovir 5-10 mg/kg IV every 8 hours 3, 5

• Duration: 5-7 days or until clinical resolution 6, 5
• Indications for IV therapy include:
  • Widespread eruptions with systemic symptoms (fever, malaise, poor oral intake) 7
  • Ocular involvement 8, 9
  • Complications such as disseminated infection, encephalitis, pneumonitis, or hepatitis 6
  • Inability to tolerate oral medications

After lesions begin to regress, transition to oral acyclovir and continue until lesions completely heal 3

Special Considerations

Ocular Involvement

When herpetic keratoconjunctivitis accompanies eczema herpeticum, use combined systemic acyclovir plus topical trifluridine 8. This combination achieves rapid resolution (48-72 hours) without residual scarring 8. Ocular involvement can progress to orbital cellulitis despite oral therapy, requiring escalation to IV acyclovir and close ophthalmologic monitoring 9.

Immunocompromised Patients

• Higher doses may be needed: acyclovir 400 mg orally 3-5 times daily 5
• Continue therapy until complete clinical resolution 5
• For severe cases: acyclovir 5 mg/kg IV every 8 hours 5

Acyclovir-Resistant HSV

If lesions persist despite acyclovir treatment, suspect resistance and use:

• Foscarnet 40 mg/kg IV every 8 hours until clinical resolution 3, 5
• Alternative: Topical cidofovir gel 1% applied daily for 5 consecutive days 5

Clinical Course and Monitoring

• Fever typically resolves within 24 hours of initiating acyclovir 1
• New lesion formation should cease by day 3 1
• Complete re-epithelialization occurs after 10 days of treatment 1
• Do not stop therapy prematurely—continue until all lesions have completely healed to prevent relapse

Common Pitfalls

1. Misdiagnosis as bacterial superinfection: Eczema herpeticum is frequently mistaken for impetigo or bacterial cellulitis, leading to inappropriate antibiotic-only treatment 1, 2. The monomorphic nature of vesiculopustules and rapid dissemination distinguish it from bacterial infection.

2. Waiting for laboratory confirmation: PCR from vesicular fluid is the preferred diagnostic test when available, but treatment must begin immediately based on clinical suspicion 1. Laboratory confirmation should never delay antiviral therapy.

3. Underestimating severity: Even patients who appear stable can deteriorate rapidly. Admit patients with widespread eruptions, systemic symptoms, or any ocular involvement for IV therapy 7, 9.

4. Inadequate duration: Treatment must continue until complete healing, not just symptomatic improvement. Premature discontinuation risks relapse and complications.